发明公开
EP1899463A2 BIOMARKERS FOR EVALUATING LIKELIHOOD OF TUMOR SENSITIVITY TO AN MTOR INHIBITOR
审中-公开
生物标志物评价中敏感性的肿瘤的的概率任何mTOR抑制剂
- 专利标题： BIOMARKERS FOR EVALUATING LIKELIHOOD OF TUMOR SENSITIVITY TO AN MTOR INHIBITOR
- 专利标题（中）： 生物标志物评价中敏感性的肿瘤的的概率任何mTOR抑制剂
-
申请号： EP06759344.2申请日： 2006-05-08
-
公开(公告)号： EP1899463A2公开(公告)日： 2008-03-19
- 发明人: BEDROSIAN, Camille, L. , CLACKSON, Timothy, P. , RIVERA, Victor
- 申请人： ARIAD GENE THERAPEUTICS, INC.
- 申请人地址： 26 Landsdowne Street Cambridge, MA 02139 US
- 专利权人： ARIAD GENE THERAPEUTICS, INC.
- 当前专利权人： ARIAD GENE THERAPEUTICS, INC.
- 当前专利权人地址： 26 Landsdowne Street Cambridge, MA 02139 US
- 代理机构： Denison, Christopher Marcus
- 优先权： US679435P 20050509; US679965P 20050510; US680978P 20050513
- 国际公布： WO2006122053 20061116
- 主分类号： C12N15/09
- IPC分类号： C12N15/09
摘要：
The present invention provides compositions and methods for evaluating the likelihood that a tumor is sensitive to an mTOR inhibitor, e.g., rapamycin or a rapamycin analog. The invention provides FKBP proteins as biomarkers for predicting the likelihood that a tumor is sensitive to an mTOR inhibitor. The methods include assessing the expression or activity of an FKBP protein, e.g., FKBP 12, in a subject with a tumor or in a sample derived from a tumor. Additional biomarkers and biomarker combinations are also provided. The invention also provides kits containing, e.g., a validated antibody or ligand for assessing the expression or activity of an FKBP protein.
信息查询
IPC分类:
